acadia pharmaceuticals inc. - ACAD
ACAD
Close Chg Chg %
16.18 0.19 1.17%
Closed Market
16.37
+0.19 (1.17%)
Volume: 1.40M
Last Updated:
Nov 22, 2024, 4:00 PM EDT
Company Overview: acadia pharmaceuticals inc. - ACAD
ACAD Key Data
| Open $16.15 | Day Range 16.01 - 16.69 |
| 52 Week Range 14.15 - 32.59 | Market Cap $2.69B |
| Shares Outstanding 166.39M | Public Float 164.32M |
| Beta 0.38 | Rev. Per Employee N/A |
| P/E Ratio 20.95 | EPS $0.78 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.41M |
ACAD Performance
| 1 Week | -3.52% | ||
| 1 Month | 12.83% | ||
| 3 Months | 1.51% | ||
| 1 Year | -27.41% | ||
| 5 Years | -65.63% |
ACAD Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
20
Full Ratings ➔
About acadia pharmaceuticals inc. - ACAD
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
ACAD At a Glance
ACADIA Pharmaceuticals, Inc.
12830 El Camino Real
San Diego, California 92130-3331
| Phone | 1-858-558-2871 | Revenue | 726.44M | |
| Industry | Pharmaceuticals: Major | Net Income | -61,286,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 40.446% | |
| Fiscal Year-end | 12 / 2024 | Employees | 598 | |
| View SEC Filings |
ACAD Valuation
| P/E Current | 20.945 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.061 |
| Price to Book Ratio | 11.94 |
| Price to Cash Flow Ratio | 307.099 |
| Enterprise Value to EBITDA | -69.994 |
| Enterprise Value to Sales | 6.535 |
| Total Debt to Enterprise Value | 0.012 |
ACAD Efficiency
| Revenue/Employee | 1,214,777.592 |
| Income Per Employee | -102,484.95 |
| Receivables Turnover | 7.098 |
| Total Asset Turnover | 1.087 |
ACAD Liquidity
| Current Ratio | 2.423 |
| Quick Ratio | 2.282 |
| Cash Ratio | 1.726 |
ACAD Profitability
| Gross Margin | 93.705 |
| Operating Margin | -10.101 |
| Pretax Margin | -7.026 |
| Net Margin | -8.437 |
| Return on Assets | -9.169 |
| Return on Equity | -14.729 |
| Return on Total Capital | -12.534 |
| Return on Invested Capital | -13.142 |
ACAD Capital Structure
| Total Debt to Total Equity | 13.249 |
| Total Debt to Total Capital | 11.699 |
| Total Debt to Total Assets | 7.638 |
| Long-Term Debt to Equity | 11.071 |
| Long-Term Debt to Total Capital | 9.776 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Acadia Pharmaceuticals Inc. - ACAD
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 441.75M | 484.14M | 517.24M | 726.44M | |
Sales Growth
| +30.28% | +9.60% | +6.83% | +40.45% | |
Cost of Goods Sold (COGS) incl D&A
| 11.69M | 11.95M | 10.17M | 45.73M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 2.93M | 3.34M | 2.03M | 5.55M | |
Depreciation
| 1.46M | 2.24M | 2.03M | 1.46M | |
Amortization of Intangibles
| - | 1.48M | 1.11M | 4.09M | |
COGS Growth
| +3.03% | +2.25% | -14.94% | +349.84% | |
Gross Income
| 430.07M | 472.19M | 507.07M | 680.71M | |
Gross Income Growth
| +31.23% | +9.80% | +7.39% | +34.24% | |
Gross Profit Margin
| +97.35% | +97.53% | +98.03% | +93.70% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 663.85M | 642.63M | 730.66M | 754.09M | |
Research & Development
| 266.33M | 239.41M | 361.57M | 351.62M | |
Other SG&A
| 397.52M | 403.22M | 369.09M | 402.47M | |
SGA Growth
| +15.60% | -3.20% | +13.70% | +3.21% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 52.80M | - |
EBIT after Unusual Expense
| (286.59M) | (170.44M) | (223.60M) | (73.38M) | |
Non Operating Income/Expense
| 5.61M | 2.92M | 10.15M | 22.34M | |
Non-Operating Interest Income
| 6.61M | 591.00K | 6.61M | 17.23M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (280.97M) | (167.52M) | (213.44M) | (51.04M) | |
Pretax Income Growth
| -19.88% | +40.38% | -27.41% | +76.09% | |
Pretax Margin
| -63.60% | -34.60% | -41.27% | -7.03% | |
Income Tax
| 611.00K | 351.00K | 2.53M | 10.25M | |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (281.58M) | (167.87M) | (215.97M) | (61.29M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (281.58M) | (167.87M) | (215.97M) | (61.29M) | |
Net Income Growth
| -19.69% | +40.38% | -28.66% | +71.62% | |
Net Margin Growth
| -63.74% | -34.67% | -41.76% | -8.44% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (281.58M) | (167.87M) | (215.97M) | (61.29M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (281.58M) | (167.87M) | (215.97M) | (61.29M) | |
EPS (Basic)
| -1.7898 | -1.046 | -1.3358 | -0.3741 | |
EPS (Basic) Growth
| -11.99% | +41.56% | -27.71% | +71.99% | |
Basic Shares Outstanding
| 157.33M | 160.49M | 161.68M | 163.82M | |
EPS (Diluted)
| -1.7898 | -1.046 | -1.3358 | -0.3741 | |
EPS (Diluted) Growth
| -11.99% | +41.56% | -27.71% | +71.99% | |
Diluted Shares Outstanding
| 157.33M | 160.49M | 161.68M | 163.82M | |
EBITDA
| (230.85M) | (167.09M) | (221.57M) | (67.83M) | |
EBITDA Growth
| +5.30% | +27.62% | -32.60% | +69.39% | |
EBITDA Margin
| -52.26% | -34.51% | -42.84% | -9.34% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 25.00 | |
| Number of Ratings | 20 | Current Quarters Estimate | 0.231 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 0.727 | |
| Last Quarter’s Earnings | 0.20 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.37 | Next Fiscal Year Estimate | 0.763 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 20 | 7 | 19 | 20 |
| Mean Estimate | 0.23 | 0.03 | 0.73 | 0.76 |
| High Estimates | 0.72 | 0.15 | 1.17 | 1.25 |
| Low Estimate | -0.07 | -0.21 | 0.42 | 0.24 |
| Coefficient of Variance | 96.67 | 411.75 | 28.45 | 36.15 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 12 | 12 | 12 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 6 | 6 | 5 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 1 | 1 | 1 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Acadia Pharmaceuticals Inc. - ACAD
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Acadia Pharmaceuticals Inc. - ACAD
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 12, 2024 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 12, 2024 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | 34,564 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $14.79 per share | 511,201.56 |
| Jun 12, 2024 | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | 35,539 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 6, 2024 | Brendan P. Teehan EVP, COO, HEAD OF COMMERCIAL | 20,445 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 6, 2024 | Brendan P. Teehan EVP, COO, HEAD OF COMMERCIAL | 42,133 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $16.94 per share | 713,733.02 |
| May 6, 2024 | Brendan P. Teehan EVP, COO, HEAD OF COMMERCIAL | 45,610 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 6, 2024 | James K. Kihara PRINCIPAL ACCOUNTING OFFICER | 7,788 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 6, 2024 | James K. Kihara PRINCIPAL ACCOUNTING OFFICER | 14,370 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $16.94 per share | 243,427.80 |
| May 6, 2024 | James K. Kihara PRINCIPAL ACCOUNTING OFFICER | 15,696 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 6, 2024 | Stephen R. Davis CEO; Director | 67,173 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 6, 2024 | Stephen R. Davis CEO; Director | 155,231 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $16.94 per share | 2,629,613.14 |
| May 6, 2024 | Stephen R. Davis CEO; Director | 166,658 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 10, 2024 | Stephen R. Davis CEO; Director | 138,666 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 10, 2024 | Stephen R. Davis CEO; Director | 34,667 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 10, 2024 | Stephen R. Davis CEO; Director | 144,267 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.87 per share | 2,578,051.29 |
| Apr 10, 2024 | James K. Kihara PRINCIPAL ACCOUNTING OFFICER | 13,100 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $17.87 per share | 234,097.00 |
| Apr 10, 2024 | James K. Kihara PRINCIPAL ACCOUNTING OFFICER | 4,020 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 10, 2024 | James K. Kihara PRINCIPAL ACCOUNTING OFFICER | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 9, 2024 | Jennifer J. Rhodes EVP, CHIEF LEGAL OFFICER, SEC | 25,889 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 9, 2024 | Jennifer J. Rhodes EVP, CHIEF LEGAL OFFICER, SEC | 126,589 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |